AC Immune S.A.
ACIU · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $1 | $1 | $1 | $1 |
| % Growth | -28.1% | 31.9% | -12.9% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $1 | $1 | $1 | $1 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $13 | $17 | $16 | $16 |
| G&A Expenses | $4 | $4 | $4 | -$2 |
| SG&A Expenses | $4 | $4 | $4 | -$2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | $0 | $6 |
| Operating Expenses | $17 | $21 | $20 | $20 |
| Operating Income | -$16 | -$19 | -$19 | -$19 |
| % Margin | -1,721.6% | -1,484.5% | -1,956.6% | -1,637.5% |
| Other Income/Exp. Net | $0 | -$2 | $0 | $3 |
| Pre-Tax Income | -$16 | -$21 | -$19 | -$16 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$16 | -$21 | -$19 | -$16 |
| % Margin | -1,688.8% | -1,622.4% | -1,922.1% | -1,389.4% |
| EPS | -0.16 | -0.21 | -0.19 | -0.14 |
| % Growth | 23.8% | -10.5% | -35.7% | – |
| EPS Diluted | -0.16 | -0.21 | -0.19 | -0.15 |
| Weighted Avg Shares Out | 99 | 101 | 100 | 110 |
| Weighted Avg Shares Out Dil | 99 | 101 | 100 | 101 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $1 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $1 | $1 | $1 |
| EBITDA | -$16 | -$21 | -$18 | -$15 |
| % Margin | -1,652.6% | -1,570.9% | -1,854.8% | -1,339.9% |